Today, Heyu Pharmaceutical is officially listed on the Hong Kong Stock Exchange

According to a recent announcement by Abbisko, the company will be officially listed on the Hong Kong Stock Exchange today (October 13)

Screenshot source: reference [2]

Heyu Medicine was established in 2016, the founder and CEO is Dr.

The company has established a pipeline of 14 drug candidates focused on oncology, including 5 drug candidates in the clinical stage

According to the prospectus, the net proceeds from Heyu Pharmaceutical's IPO will be used for the following purposes:

About 19.

Core candidate product ABSK011

About 32.

Core candidate product ABSK091 (AZD4547)

About 28.

Approximately 8.

Heyu Pharmaceutical Product Pipeline (Source of screenshots: Reference [3])

Possess a series of FGFR pipeline combinations

Possess a series of FGFR pipeline combinations

According to the prospectus, Heyu Medicine has a series of fibroblast growth factor receptor (FGFR) pipeline portfolio, covering multiple types of wild-type and mutant FGFR isoforms

Pan-FGFR inhibitors targeting specific FGFR subtypes of FGFR inhibitors A new generation of FGFR inhibitors

ABSK011 : Highly selective FGFR4 small molecule oral inhibitor developed by Heyu Medicine , which can inhibit the growth of tumors by inhibiting the activity of FGFR4 and blocking related signal transduction

ABSK011 Highly Selective FGFR4 Small Molecule Oral Inhibitor

ABSK091 (AZD4547) : A selective inhibitor of FGFR subtypes 1, 2 and 3.

ABSK091 (AZD4547) A selective inhibitor of FGFR subtypes 1, 2 and 3.

Other clinical stage drug candidates

In addition to FGFR candidate drugs, Heyu Medicine also formed a small molecule tumor immunotherapy candidate drug combination, targeting the main tumor microenvironmental immune cell types, including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSC) , Treg cells, Th17/Tc17 cells and effector T cells

Image source: 123RF

ABSK021: A selective small molecule CSF-1R inhibitor , which is being developed for the treatment of various types of tumors and non-tumor indications

ABSK021: a selective small molecule CSF-1R inhibitor

ABSK081 (mavorixafor): an oral CXCR4 antagonist

ABSK081 (mavorixafor): an oral CXCR4 antagonist

ABSK043: A highly selective small molecule PD-L1 inhibitor , which is being developed to treat a variety of cancers and potential non-tumor indications

ABSK043: A highly selective small molecule PD-L1 inhibitor

references:

references:

[1]02256-Heyu-B-New listing.

[1]02256-Heyu-B-New listing.

[2] Announcement of Offer Price and Allocation Results.
Retrieved Oct 11.
2021.
from hhttps://pdf.
dfcfw.
com/pdf/H2_AN202110121522101007_2.
pdf?1634027871000.
pdf

[3] Heyu Pharmaceutical Prospectus.
From https://www2.
hkexnews.
hk/New-Listings/New-Listing-Information/Main-Board?sc_lang=zh-HK

[3] Heyu Pharmaceutical Prospectus.
From https://www2.
hkexnews.
hk/New-Listings/New-Listing-Information/Main-Board?sc_lang=zh-HK